Should You Stop GLP-1s Before Surgery? Anesthesia & Aspiration Risk Evidence

If you take Ozempic, Wegovy, Mounjaro, Zepbound, or any other GLP-1 medication and have surgery coming up, you have probably been told to stop the drug first. The reason is aspiration risk: these drugs slow how fast your stomach empties, so food can linger long after the usual overnight fast and end up in your lungs while you are sedated. The guidance has shifted twice in two years, and a 2026 randomized trial finally gave doctors real numbers instead of guesses about how big the risk actually is.

The Short Version of a Confusing Story

The advice on GLP-1s before surgery has changed direction more than once, and that whiplash is the main reason patients are confused.

In June 2023, the American Society of Anesthesiologists (ASA) told patients to stop their GLP-1 entirely before any procedure under sedation or general anesthesia. In October 2024, five medical societies including the ASA walked that back and said most people can keep taking their medication, with extra precautions for higher-risk patients. Then in 2026, a randomized trial showed that continuing the drug really does leave more food in the stomach, which pushed some doctors back toward holding it.

So the honest answer is: it depends on your dose, your symptoms, the type of procedure, and what your own anesthesia and surgical team decides. This article walks through the mechanism, the actual evidence, and what the major guidelines say so you can have an informed conversation with your care team. It is not a substitute for that conversation.

Why GLP-1s Raise Aspiration Concerns in the First Place

GLP-1 receptor agonists work partly by slowing gastric emptying. That is one of the reasons they reduce appetite: food sits in your stomach longer, so you feel full sooner and stay full longer. For weight loss and blood sugar control, that delay is a feature. Before anesthesia, it becomes a problem.

Standard pre-surgery fasting rules assume a normal stomach. You stop solid food for about eight hours and clear liquids for two, and by the time you go under, your stomach is empty. An empty stomach matters because anesthesia and deep sedation switch off the reflexes that normally keep stomach contents from coming back up and going down the windpipe. If food or fluid is still sitting there, it can be regurgitated and inhaled into the lungs. That is pulmonary aspiration, and it can cause a serious chemical pneumonia (called aspiration pneumonitis) or, rarely, a blocked airway.

The worry with GLP-1s is straightforward: if the drug keeps the stomach full past the usual fasting window, the standard fasting rules may not protect you. The harder question is how often that actually leads to harm.

It helps to understand how big the delay can be. In healthy people, a solid meal clears the stomach in a few hours. GLP-1s can stretch that, and the effect is strongest soon after a dose and during the weeks when the dose is being increased. Over months on a stable dose, the body partly adapts and emptying speeds back up somewhat. That is why a person who started the drug three weeks ago is, on average, a different risk than someone who has been on the same maintenance dose for a year. The drug is the same; the timing is not.

For a broader look at how delayed gastric emptying behaves on these drugs, see our evidence review on GLP-1s and gastroparesis (stomach paralysis).

What the Evidence Actually Shows

Here is where it pays to separate two different things: how much food is left in the stomach (called residual gastric content or residual gastric volume), and how often patients actually aspirate. The drugs clearly raise the first. Whether they raise the second is far less settled. Getting this distinction right is the whole point.

Residual Gastric Content: The Signal Is Strong

Multiple studies and meta-analyses agree that people on GLP-1s have more food left in the stomach after standard fasting than people who are not.

A 2025 meta-analysis in Digestive and Liver Disease pooled 39 studies covering more than 1.25 million patients and found that GLP-1 users had roughly five times the odds of retained gastric content compared with non-users (odds ratio about 4.86). A real-world endoscopy study of just over 1,000 patients found retained stomach contents in 13.7% of GLP-1 users versus 1.5% of non-users — about nine times the odds. In that study, tirzepatide showed the highest rate of retained food.

The strongest evidence is the 2026 OCULUS randomized trial, published in JAMA Internal Medicine. Researchers at two U.S. tertiary centers randomly assigned 60 adults on stable GLP-1 or GLP-1/GIP therapy to either continue the drug or hold one dose before an elective upper endoscopy. Clinically significant residual gastric volume showed up in 25% of those who continued versus 3.1% of those who held a single dose. The difference was large enough that the trial was stopped early for safety. This is the cleanest signal yet that the drug itself, not just the underlying condition, drives the retained food.

Actual Aspiration: The Signal Is Weak and Inconsistent

This is the part that gets lost in headlines. More food in the stomach is a risk factor for aspiration, but it is not the same as aspiration. Most studies that looked for actual aspiration events did not find a clear increase.

A 2025 meta-analysis in Anaesthesia pooled 9 studies with more than 185,000 patients and 471 aspiration cases. It found no association between GLP-1 use and pulmonary aspiration (odds ratio 1.04, meaning essentially no difference), though the authors rated the certainty of that evidence as low. The large real-world endoscopy study reached the same conclusion: more retained food, but no measurable jump in aspiration.

The picture is not unanimous. The 2025 Digestive and Liver Disease meta-analysis did report a higher aspiration odds ratio (about 2.29) in the endoscopy setting. The difference likely comes down to which procedures were studied, how aspiration was defined, and the rarity of the event, which makes it statistically hard to measure. Aspiration during anesthesia is uncommon to begin with, so even doubling a tiny number leaves a small absolute risk.

The fair summary: GLP-1s reliably leave more food in your stomach (high-quality evidence), and that retained food can interrupt procedures or force a repeat endoscopy (consistent evidence), but a clear, large increase in actual aspiration pneumonia has not been proven (low-certainty, mixed evidence).

The Evidence at a Glance

Outcome	What the evidence shows	Strength of evidence
Retained stomach contents	Roughly 5x higher odds (OR ~4.86 across 1.25M+ patients); 13.7% vs 1.5% in real-world endoscopy	Strong and consistent
Residual volume by drug type	Tirzepatide and weekly agents tend to leave the most; held dose cuts it sharply	Moderate
Interrupted or aborted procedure	More likely in GLP-1 users; some endoscopies must be repeated	Consistent
Actual pulmonary aspiration	No clear increase in surgery (OR ~1.04); mixed in endoscopy (OR ~2.29); event is rare	Low and inconsistent
Holding one dose before EGD	Cut clinically significant residual volume from 25% to 3.1% in a randomized trial	Strong (single RCT)

How the Official Guidance Evolved

The guidance has moved as the evidence came in, which is why your surgeon, your endoscopist, and your prescriber may not all say the same thing.

Period	Guidance	Practical meaning
Before mid-2023	No specific guidance	Standard fasting only; GLP-1s often not even mentioned
June 2023	ASA: hold the drug — 1 day before for daily forms, 1 week before for weekly forms	Blanket stop for everyone before sedation or general anesthesia
October 2024	Five-society guidance: most patients continue; add precautions for higher-risk patients	Shared decision-making, not a blanket rule
2026 onward	OCULUS RCT data revive the case for holding before upper endoscopy	Some centers again hold a dose, especially for EGD

The 2023 ASA Position: Stop the Drug

In June 2023, the ASA issued consensus guidance telling patients to hold daily GLP-1s on the day of the procedure and weekly GLP-1s for one week before any elective procedure under anesthesia or deep sedation. It was cautious by design, and the ASA acknowledged it was based on limited evidence and concern rather than proof of harm.

The 2024 Multisociety Reversal: Most Patients Can Continue

In October 2024, five organizations — the ASA, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons — issued joint guidance reversing the blanket-stop approach.

The core idea: stopping the drug carries its own costs. People take GLP-1s for diabetes and serious metabolic disease, and abruptly holding them can disrupt blood sugar control and weight management. Routinely stopping these drugs before every minor procedure was not justified by the (then weak) aspiration evidence. So the new guidance favors shared decision-making among the patient, the prescriber, the anesthesia team, and the proceduralist, weighing the metabolic need to stay on the drug against each patient's individual risk.

The guidance flagged specific things that raise risk:

Being in the dose-escalation phase rather than a stable maintenance dose
Higher doses
Weekly formulations (longer-acting) more than daily ones
GI symptoms such as nausea, vomiting, bloating, abdominal pain, or constipation

For higher-risk patients, the recommended mitigations include a 24-hour clear liquid diet before the procedure, gastric ultrasound to check for retained contents on the day, and treating the patient as a "full stomach" with rapid-sequence induction if general anesthesia is used.

Why the 2026 Data Muddied It Again

The OCULUS trial landed after the 2024 reversal and showed that continuing the drug really does leave clinically significant residual volume far more often. That does not undo the 2024 logic — actual aspiration is still rare and stopping the drug has real downsides — but it strengthened the case for holding a dose specifically before upper endoscopy, where a full stomach also wrecks the exam. Expect your endoscopist to be more cautious than your orthopedic surgeon. The procedure type matters.

What This Means for Different Procedures

Not all procedures carry the same concern, and the right move depends heavily on what you are having done.

Upper endoscopy (EGD). This is the highest-concern setting, for two reasons. Retained food can directly block the view, forcing the doctor to abort and repeat the procedure, and the upper GI tract is exactly where aspiration originates. The OCULUS data argue for holding a dose here. Many GI centers now ask GLP-1 patients to hold the most recent dose and follow a clear liquid diet beforehand.

Colonoscopy alone. The bowel prep already empties you out with liters of liquid, and you are on clear liquids for a day anyway. Concern is lower. Talk to your team, but a full stomach is less likely after standard prep.

General surgery under general anesthesia. Risk is managed mainly by the anesthesia team. They may use gastric ultrasound, a 24-hour liquid diet, or rapid-sequence induction (a technique that protects the airway quickly) rather than insisting you stop the drug weeks out. For major or emergency surgery, the metabolic stakes of stopping the drug get weighed against aspiration risk case by case.

Minor procedures with light sedation only. When you are not deeply sedated and keep your protective reflexes, the concern is much smaller. Procedures done under local anesthesia with no sedation carry essentially the standard, low background risk, because you keep full control of your airway the entire time.

One more practical point: emergency surgery is a different situation entirely. You cannot plan a 24-hour liquid diet or hold a dose before a true emergency. In that case the team simply treats you as a full-stomach patient and uses airway-protection techniques. The detailed planning in this article applies to elective and scheduled procedures, where you and your team have time to make a thoughtful choice.

Comparing Your Options Before a Procedure

There is no single right answer, only a set of trade-offs your team will weigh with you.

Option 1: Continue the drug, add precautions. Favored by the 2024 guidance for most patients, especially on stable doses with no GI symptoms. Precautions include a 24-hour clear liquid diet, gastric ultrasound on the day, and full-stomach anesthesia technique. Upside: no disruption to diabetes or weight control. Downside: higher chance of retained food and a possibly aborted endoscopy.

Option 2: Hold one dose. Supported by the OCULUS trial for upper endoscopy. Holding a single weekly dose dropped clinically significant residual volume from 25% to 3.1%. Upside: much cleaner stomach. Downside: a short gap in therapy, which for most people on a stable dose is minor. For people with brittle diabetes, even a short gap needs planning.

Option 3: Hold for a full week (the old 2023 approach). Now generally considered more than necessary for most patients and disruptive to metabolic control. Some teams still use it for specific high-risk cases.

The single most useful thing you can do is tell every member of your care team that you are on a GLP-1, the exact drug, your current dose, when your last dose was, and whether you have any GI symptoms. That information drives the whole decision.

Safety: How to Lower Your Own Risk

You cannot control the guidelines, but you can control how clearly you communicate and how well you prep.

Disclose the drug early. Tell the surgical scheduler, your prescriber, the anesthesiologist, and the proceduralist. Do not assume one told the others.
Know your details. Drug name, dose, daily or weekly, date of last dose. Write it down.
Report GI symptoms honestly. Nausea, vomiting, bloating, fullness, or feeling like food sits in your stomach all raise the risk. Hiding them does not help you.
Follow the prep instructions exactly. If you are told to do a 24-hour clear liquid diet, take it seriously. It measurably lowers retained contents.
Do not stop a diabetes medication on your own. If you take a GLP-1 for type 2 diabetes, holding it without a plan can spike your blood sugar. Coordinate with your prescriber.
Ask about gastric ultrasound. If you are higher risk, ask whether your team can scan your stomach before sedation. It is a quick, noninvasive check.

If you are weighing a longer pause for other reasons, our guide on stopping semaglutide and what to expect covers the metabolic side. And because GLP-1s slow gastric emptying enough to affect how other oral drugs are absorbed, see GLP-1 drug interactions to know.

Who Should Be Most Careful

Some patients sit clearly on the higher-risk end and deserve extra caution.

People in the dose-escalation phase. GI side effects and gastric delay are worst in the first weeks and after each dose bump. If your surgery is elective, doing it during a stable maintenance dose is safer.
People on high doses or weekly formulations. Longer-acting weekly drugs keep the stomach slower for longer.
People with active GI symptoms. Ongoing nausea, vomiting, or fullness signals a slow stomach right now.
People with known gastroparesis or prior retained contents. A documented slow stomach changes the math.
People having upper endoscopy. The procedure most affected by retained food.

Lower-risk patients — stable maintenance dose, no GI symptoms, a non-GI procedure under light sedation — can often continue with simple precautions. For the full menu of GLP-1 side effects beyond the surgical setting, see our complete GLP-1 side effects guide. And if drug choice itself is on the table, our comparison of switching from Ozempic to Mounjaro covers the differences between agents.

Frequently Asked Questions

How long before surgery should I stop my GLP-1?

There is no universal number anymore. The old 2023 rule was one day for daily drugs and one week for weekly drugs. The 2024 multisociety guidance moved away from a blanket rule toward case-by-case decisions, and 2026 trial data support holding at least one dose before upper endoscopy. Ask your specific anesthesia and surgical team — the right answer depends on your drug, dose, symptoms, and procedure.

Does stopping my GLP-1 before surgery hurt my diabetes or weight loss?

A short pause of one dose rarely causes lasting harm to weight loss. For type 2 diabetes, even a brief gap can raise blood sugar, so never stop on your own — coordinate with the prescriber who manages your diabetes so they can adjust other medications if needed.

Is the aspiration risk actually proven?

Partly. The evidence that GLP-1s leave more food in the stomach is strong and consistent. The evidence that this translates into more actual aspiration events is weak and mixed. One large surgery meta-analysis found no increase; one endoscopy meta-analysis found a higher rate. Actual aspiration is rare either way, which makes it hard to measure precisely.

What can my anesthesia team do if I keep taking the drug?

Several things. They can have you follow a 24-hour clear liquid diet, scan your stomach with gastric ultrasound on the day to check for retained food, and use rapid-sequence induction to protect your airway quickly during general anesthesia. These steps let many patients safely continue their medication.

Does this apply to all GLP-1 drugs equally?

The concern applies across the class — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, dulaglutide, and others. Some data suggest tirzepatide and longer-acting weekly drugs leave the most retained food, and higher doses and the escalation phase raise risk most. Daily, lower-dose, stable use tends to be lower risk.

This article is for general education and is not medical advice. Decisions about stopping or continuing any medication before surgery should be made with your prescribing doctor, surgeon, and anesthesia team.